Showing 2461-2470 of 3315 results for "".
- Atsena Granted FDA Regenerative Medicine Advanced Therapy Designation for Gene Therapy to Treat X-Linked Retinoschisishttps://modernod.com/news/atsena-therapeutics-granted-fda-regenerative-medicine-advanced-therapy-designation-gene-therapy-to-treat-x-linked-retinoschisis/2482737/Atsena Therapeutics announced that the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation for ATSN-201 for the treatment of X-linked retinoschisis (XLRS). ATSN-201, a gene therapy product candidate, leverages AAV.SPR, the company’s novel spreading capsid, to
- Andrew Chang Joins BVI Medical as Chief Commercial Officerhttps://modernod.com/news/andrew-chang-joins-bvi-medical-as-chief-commercial-officer/2482735/BVI Medical announced the appointment of Andrew Chang to the newly created role of Chief Commercial Officer. Mr. Chang will lead the company’s global sales, global marketing, and commercial excellence teams and will report directly to President and CEO Shervin Korangy. Mr. Ch
- Eye Foundation of America Hosts Fundraising Galahttps://modernod.com/news/eye-foundation-of-america-hosts-fundraising-gala/2482734/On April 12, the Eye Foundation of America is hosting a Spring fundraiser gala in New Rochelle, New York. Under the leadership of Surendra Sharma, MD and Rachana Shukla, MD, the group hopes to raise funds to help support a new state-of-the-art green hospital in India, as well
- FDA Once Again Rejects Aldeyra's NDA of Reproxalap for Dry Eye Diseasehttps://modernod.com/news/fda-once-again-rejects-aldeyras-nda-of-reproxalap-for-dry-eye-disease/2482727/The FDA issued a complete response letter declining to approve Aldeyra Therapeutics' resubmitted new drug application (NDA) of reproxalap, an investigational drug candidate for the treatment of dry eye disease. Although no manufacturing or safety issues with repr
- Atsena Therapeutics Secures $150 Million to Advance Investigational Ocular Gene Therapyhttps://modernod.com/news/atsena-therapeutics-secures-150-million-to-advance-investigational-ocular-gene-therapy/2482726/Atsena Therapeutics has closed an oversubscribed $150 million Series C financing, which will be used to advance Atsena’s lead gene therapy program, ATSN-201, aimed at treating X-linked retinoschisis (XLRS). Additionally, the funds will support Atsena’s preclinic
- Alcon Launches Clareon PanOptix Pro Trifocal IOLhttps://modernod.com/news/alcon-launches-clareon-panoptix-pro-trifocal-iol/2482725/Alcon has introduced the Clareon PanOptix Pro IOL in the US. According to Alcon, PanOptix Pro leverages proprietary 'ENLIGHTEN NXT' Optical technology, which is designed
- Bausch + Lomb Announces Voluntary Recall of enVista IOLshttps://modernod.com/news/bausch-lomb-announces-voluntary-recall-of-envista-iols/2482717/In response to an increased number of reports of toxic anterior segment syndrome (TASS), Bausch + Lomb announced a voluntary recall of IOLs on its enVista platform, including the enVista Aspire and enVista Envy IOLs, and certain enVista monofocal lenses in the US. B+
- Study: Glaucoma Monitoring Lags in Low-Income and Rural Areashttps://modernod.com/news/study-glaucoma-monitoring-lags-in-low-income-and-rural-areas/2482710/A new Northwestern University study suggests that race, income and where patients live play a major role in the level of care glaucoma patients receive. Researchers found that Black, Hispanic and Asian American patients, as well as those from rural and economically distressed communities, are sig
- Lighthouse Guild Appoints Thomas Panek as New President and CEOhttps://modernod.com/news/lighthouse-guild-appoints-thomas-panek-as-new-president-and-ceo/2482706/Lighthouse Guild announced this morning that Thomas Panek has been appointed as President and CEO, effective April 2025. He succeeds Dr. Calvin W. Roberts, who has served in this role for the past 5 years. Mr. Panek has significant leadership experience with a deep commitment to a
- Atsena Granted FDA Fast Track Designation for Gene Therapy to Treat X-linked Retinoschisishttps://modernod.com/news/atsena-therapeutics-granted-fda-fast-track-designation-for-gene-therapy-to-treat-x-linked-retinoschisis/2482699/Atsena Therapeutics announced that the FDA has granted Fast Track designation for gene therapy product candidate, ATSN-201, for the treatment of X-linked retinoschisis (XLRS). ATSN-201 leverages AAV.SPR, the company’s novel spreading capsid, to achieve therapeutic levels of g